Recombinant human erythropoietin in anemia associated with pediatric cancer: Study of the identification of predictors of response;Eritropoyetina recombinante humana en la anemia asociada al cancer infantil: Estudio de la identificacion de factores predictivos de la respuesta

Anales Espanoles de Pediatria

Volumn 49, Issue 1, 1998, Pages 17-22

  Leon Molinari P ^a   Jimenez Monteagudo M ^a   Barona Zamora, P ^a   Riol Diego, M ^a   Castro Paz, L ^a   Sierrasesumaga Ariznavarreta L ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Anemia; Cancer; Chemotherapy; Recombinant human erythropoietin

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACTINOMYCIN; DOXORUBICIN; ERYTHROPOIETIN; HEMOGLOBIN; HYDROXYUREA; IFOSFAMIDE; MELPHALAN; METHOTREXATE; PREDNISONE; PROCARBAZINE; RECOMBINANT ERYTHROPOIETIN; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; PREDICTION; SOLID TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADOLESCENT; ANEMIA; ANTINEOPLASTIC AGENTS; CHILD; DISEASE PROGRESSION; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMOGLOBINS; HUMANS; MALE; NEOPLASMS; PILOT PROJECTS; PROGNOSIS; TREATMENT OUTCOME;

EID: 7344251176     PISSN: 03024342     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Reed WR, Hussey DH, Degowin RL. Implications of the anemia of chronic disorders in patients anticipating radiotherapy. Am J Med Sci 1994; 308:9-15.
2. Means RT. Clinical application of recombinant erythropoietin in the anemia of chronic disease. Hematol Oncol Clin North Am 1994; 8:933-944.
3. Duhrsen U, Hosseld DK. Hematopoietic growth factors and the treatment of tumor-associated anemias. Ann Hematol 1994; 69:213-221.
4. Scott JM, Weir DG. Drug-induced megaloblastic change. Clin Hematol 1980; 9:587-606.
5. Zucker S. Anemia in cancer. Cancer Invest 1985; 3:249-260.
6. Steinberg D. Anemia and cancer. CA Cancer J Clin 1989; 39:296-304.
7. Podzamczer D, Vidaller A. Anemia hemolítica microangiopática asociada a cáncer. Med Clin (Barc) 1985;84:30-34.
8. Nordstrom B, Strang P. Microangiopatic hemolytic anemias (MAHA) in cancer. A case report and review. Anticancer Res 1993; 13:1845-1850.
9. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N Eng J Med 1990; 322:1689-1692.
10. Jelkmann W, Pagel H, Wolff M, Fandrey J. Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. Life Sci 1992; 50:301-308.
11. Skillings J, Sridhar F, Wong C, Paddock L. The frequency of red cell transfusion for anemia in patients receiving chemotherapy. A retrospective cohort study. Am J Clin Oncol 1993; 16:22-25.
12. Henry DH. Clinical application of recombinant erythropoietin in anemic cancer patients. Hematol Oncol Clin North Am 1994; 8:961-973.
13. Walker RH. Special report: Transfusion risk. Am J Clin Pathol 1987; 88:374-378.
14. Lackritz EM, Satten GA, Aberle-Grasse J, et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Eng J Med 1995; 333:1721-1725.
15. Dodd RY. The risk of transfusion-transmitted infection. N Eng J Med 1992; 327:419-420.
16. Klein HG. Immunologic aspects of blood transfusion. Semin Oncol 1994,21(suppl 3):16-20.
17. Barona P, Sierrasesúmaga L, Antillón F, Villa-Elízaga I. Uso de la eritropoyetina recombinante humana en la anemia por quimioterapia. Experiencia en un niño testigo de Jehová. Rev Clin Esp 1993; 193:516-517.
18. Eschbach JW, Abdulhadi M, Browne J, et al. Recombinant human erythropoietin in anemic patients with end stage renal disease. Ann Intern Med 1989; 111:992-1000.
19. Shannon K, Keith JF, Mentzer WC, et al. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics 1995; 95:1-8.
20. Phair J, Abels R, McNeill M, Sullivan D. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the adquired immunodeficiency syndrome. Arch Intern Med 1993; 153:2669-2675.
21. Locatelli F, Zecca M, Pedrazzoli P, et al. Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patiens with acute leukemia: effect on erythroid repopulation in autologous versus allogeneic transplants. Bone Marrow Transplant 1994; 13:403-410
22. Spivak JL. Recombinant human erythropoietin and its role in transfusion medicine. Transfusion 1994; 34:1-4.
23. Fantini F, Gattinara M, Gerloni V, Bergomi P, Cirla E. Severe anemia associated with active systemic-onset juvenile rheumatoid arthritis successfully treated with recombinant human erythropoietin: a pilot study. Arthritis Rheum 1992; 35:724-726.
24. Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer 1993; 29A(suppl 2):2-8.
25. Cascinu S, Fedeli A, Del Ferro E, Catalano G. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 1994; 12:1058-1062.
26. Ludwig H, Sundal E, Pecherstorfer M, et al. Recombinant human erythropoietin for the correction of cancer associated anemia with and without cytotoxic chemotherapy. Cancer 1995; 76:2319-2329.
27. Wurnig C, Windhager R, Schwameis E, et al. Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, Phase III study). Transfusion 1996; 36:155-159.
28. Cazzola M, Messinger D, Battistel V, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 1995; 86:4446-4453.
29. Beguin Y, Yema M, Loo M, Weber M, Fillet G. Erythropoiesis in multiple myeloma: defective red cell production due to inappropiate erythropoietin production. Br J Haematol 1992; 82:648-653.
30. Case DC, Bukowski RM, Carey RW, et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993; 85:801-806.
31. Ludwig H, Fritz E, Leigeb C, Pecherstorfer M, Samonigg H, Schuster J. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 1994; 84:1056-1063.
32. Nenadov Beck M, Beck D. Recombinant erythropoietin in acute chemotherapy-induced anemia of children with cancer. Med Ped Oncol 1995; 25:17-21.
33. Bryan GL, Reaman GH. Erythropoietin deficiency: a complication of cisplatin therapy and its treatment with recombinant human erythropoietin? Am J Pediatr Hemat Oncol 1991; 13:426-430.
34. Porter JC, Leahey A, Polise K, Bunin G, Manno CS. Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: a randomized, double-blind placebo-controlled trial. J Pediatr 1996; 129:656-660.
35. Kronberger M, Keck B, Zoubek A, et al. Prevention of anemia with r-HuEPO in children with Ewing's sarcoma or osteogenic sarcoma. Proc ASCO 1995; 14:258.
36. Spivak JL. Recombinant human erythropoietin and the anemia of cancer. Blood 1994; 84:997-1004.
37. Oster W, Herrmann F, Gamm H, et al. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol 1990; 8:956-962.
38. Falkson CI, Keren-Rosenberg S, Uys A, Falkson G, Stebens K, Vermaak WJH. Recombinant human erythropoietin in the treatment of cancer-related anaemia. Oncology 1994; 51:497-501.
39. Ludwig H, Fritz E, Hotzmann H, Hocker P, Gisslinger H, Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. N Eng J Med 1990; 322:1693-1699.